IL151032D0 - Integrin antagonists - Google Patents

Integrin antagonists

Info

Publication number
IL151032D0
IL151032D0 IL15103201A IL15103201A IL151032D0 IL 151032 D0 IL151032 D0 IL 151032D0 IL 15103201 A IL15103201 A IL 15103201A IL 15103201 A IL15103201 A IL 15103201A IL 151032 D0 IL151032 D0 IL 151032D0
Authority
IL
Israel
Prior art keywords
integrin antagonists
integrin
antagonists
Prior art date
Application number
IL15103201A
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US18486500P priority Critical
Application filed by Immunex Corp filed Critical Immunex Corp
Priority to PCT/US2001/005701 priority patent/WO2001062905A2/en
Publication of IL151032D0 publication Critical patent/IL151032D0/en

Links

IL15103201A 2000-02-25 2001-02-23 Integrin antagonists IL151032D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US18486500P true 2000-02-25 2000-02-25
PCT/US2001/005701 WO2001062905A2 (en) 2000-02-25 2001-02-23 Integrin antagonists

Publications (1)

Publication Number Publication Date
IL151032D0 true IL151032D0 (en) 2003-04-10

Family

ID=22678680

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15103201A IL151032D0 (en) 2000-02-25 2001-02-23 Integrin antagonists

Country Status (10)

Country Link
US (2) US7074408B2 (en)
EP (1) EP1259595B1 (en)
JP (1) JP2003523768A (en)
AT (1) AT358718T (en)
AU (2) AU4721901A (en)
CA (1) CA2400040A1 (en)
DE (1) DE60127656T2 (en)
IL (1) IL151032D0 (en)
NZ (1) NZ521437A (en)
WO (1) WO2001062905A2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
JP2001521742A (en) * 1997-10-30 2001-11-13 イミュネックス・コーポレーション Svph1-26dna and polypeptides
CA2320422A1 (en) * 1998-02-11 1999-08-19 Immunex Corporation Metalloprotease-disintegrins svph3-13 and svph3-17 dna and polypeptides
US6265199B1 (en) * 1998-07-10 2001-07-24 Zymogenetics, Inc. Disintegrin homologs
AU2507700A (en) 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
IL143769D0 (en) * 1999-01-21 2002-04-21 Immunex Corp Metalloproteinase-disintegrin family members: svph dnas and polypeptides
WO2001009189A2 (en) * 1999-07-28 2001-02-08 Genentech, Inc. Compositions and methods for the treatment of tumors
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, a novel immunoregulatory molecule
EP1268756A2 (en) * 2000-04-03 2003-01-02 Bristol-Myers Squibb Co. Methods and compositions for modulating integrin-mediated cell-cell interactions
CA2407086A1 (en) * 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
JP2004500844A (en) * 2000-05-08 2004-01-15 バイオジェン インコーポレイテッドBiogen Incorporated Using the Tweak agonists and angiogenic factors, methods for promoting neovascularization
US6458552B1 (en) * 2000-06-06 2002-10-01 Ortho-Mcneil Pharmaceutical, Inc. Metalloprotease peptide substrates and methods
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
US20050004199A1 (en) * 2000-09-18 2005-01-06 George Hartman Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
US6294368B1 (en) 2001-03-22 2001-09-25 Applera Corporation Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
FR2827775B1 (en) 2001-07-26 2003-09-26 Bioalliance Pharma Use in an anti-angiogenic composition Disintegrin Domain of adamalysin
ES2328025T3 (en) 2001-10-09 2009-11-06 Mayo Foundation For Medical Education And Research Improving immune responses by agonists antibodies 01/04 bb.
AU2003224950B2 (en) 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
US20060140933A1 (en) * 2002-08-16 2006-06-29 Wyeth And Imperial College Innovations Limited Compositions and methods for treating rage-associated disorders
CN101357230A (en) * 2003-03-04 2009-02-04 格林维尔医院系统公司 Antitumor agents comprising a targeting portion and an immune response triggering portion
US7694682B2 (en) * 2003-04-11 2010-04-13 Ambu A/S Laryngeal mask and a method manufacturing same
MEP31408A (en) 2003-07-18 2010-10-10 Abgenix Inc Specific binding agents to hepatocyte growth factor
CN102120031B (en) * 2003-08-07 2012-12-05 希尔洛有限公司 Pharmaceutical compositions and methods for accelerating wound healing
CN1993143A (en) 2004-06-04 2007-07-04 健泰科生物技术公司 Method for treating multiple sclerosis
US7507748B2 (en) * 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
PL1810026T3 (en) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-h1 and pd-1 in treatment of renal cell carcinoma
JP5328155B2 (en) 2005-02-02 2013-10-30 マクロジェニックス ウエスト, インコーポレイテッド Adam-9 modulator
CA2597945C (en) 2005-02-17 2016-07-12 Biogen Idec Ma Inc. Treating neurological disorders
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP1940440A4 (en) * 2005-08-29 2009-11-11 Healor Ltd Methods and compositions for prevention and treatment of diabetic and aged skin
US20100144641A1 (en) * 2005-09-12 2010-06-10 Popel Aleksander S Compositions Having Antiangiogenic Activity and Uses Thereof
US7354904B2 (en) * 2005-12-08 2008-04-08 The United States Of America As Represented By The Secretary Of Agriculture Bacteriocin inducer peptides
JP2009523787A (en) * 2006-01-19 2009-06-25 アイジーン インコーポレイテッド Therapeutic compositions of the vascular-related disease comprising a peptide as an active ingredient
KR100797567B1 (en) 2006-04-27 2008-01-24 연세대학교 산학협력단 Protein for inhibiting secretion of platelet granules
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE15062012A1 (en) 2006-07-14 2012-11-26 Amgen Inc triazolo compounds as inhibitors of c-met
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP1970441A1 (en) * 2007-03-06 2008-09-17 BioAlliance Pharma Plasmid containing a sequence encoding a disintegrin domain of metargidin (RDD)
BRPI0813452A2 (en) 2007-06-14 2017-05-23 Galactica Pharmaceuticals Inc RAGE fusion proteins.
JP5411857B2 (en) * 2007-07-30 2014-02-12 ヒールオア・リミテッド Pharmaceutical compositions and related methods
RS56743B1 (en) 2007-08-21 2018-03-30 Amgen Inc Human c-fms antigen binding proteins
JP5526407B2 (en) * 2008-02-14 2014-06-18 株式会社ジーンテクノサイエンス Anti-adam-15 antibody and its use
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
US9101581B2 (en) * 2008-10-27 2015-08-11 Eyegene Inc. Method for treating vascular-related disease
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
AU2010217213B2 (en) * 2009-02-24 2013-05-23 Healor Ltd. Visfatin therapeutic agents for the treatment of acne and other conditions
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
CN103083669A (en) 2010-01-11 2013-05-08 希尔洛有限公司 Method for treatment of inflammatory disease and disorder
EP2353607A1 (en) * 2010-02-04 2011-08-10 BioAlliance Pharma Use of disintegrin domain of an adamalysin for the treatment of psoriasis
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
TW201334789A (en) 2012-01-31 2013-09-01 Genentech Inc Anti-IgE antibodies and methods using same
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche Combined antibodies against CSF-1R human therapy and uses thereof
WO2013136193A2 (en) 2012-03-16 2013-09-19 University Health Network Methods and compositions for modulating toso activity
EP2890696A1 (en) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
EA201690861A1 (en) * 2012-10-24 2016-08-31 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" protein nucleic acid modulators alpha2beta1
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2015016616A1 (en) * 2013-07-30 2015-02-05 연세대학교 산학협력단 Saxatilin-fc fusion protein and use thereof
TW201605896A (en) 2013-08-30 2016-02-16 Amgen Inc GITR antigen binding proteins
WO2015050663A1 (en) 2013-10-01 2015-04-09 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of bim
WO2017001990A1 (en) * 2015-06-28 2017-01-05 Allgenesis Biotherapeutics Inc. Fusion proteins for inhibiting angiogenesis
WO2017062682A2 (en) 2015-10-06 2017-04-13 Genentech, Inc. Method for treating multiple sclerosis
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177475B1 (en) 1992-06-30 2001-01-23 Billings Pharmaceuticals, Inc. Methods of using integrin modulators for treatment of inflammation
US5731288A (en) 1993-10-22 1998-03-24 University Of Southern California Compositions containing contortrostatin and methods for the use thereof
US5814609A (en) 1993-10-22 1998-09-29 University Of Southern California Compositions containing a disintegrin and methods for its use in preventing metastasis and other conditions
US5693496A (en) 1994-06-20 1997-12-02 Merck & Co., Inc. DNA encoding the mouse and human PH30 beta chain protein
US5830742A (en) 1995-06-08 1998-11-03 Immunex Corporation TNF-α converting enzyme
US6255064B1 (en) 1996-03-01 2001-07-03 The Procter & Gamble Company Disintegrin metalloprotease and its use
EP0963432A4 (en) 1996-08-29 2002-11-20 Univ California Kuz, a novel family of metalloproteases
US6140098A (en) 1996-08-30 2000-10-31 Schering Corporation Nucleic acids encoding mammalian proteinases; related reagents
GB9716755D0 (en) 1997-08-07 1997-10-15 Glaxo Group Ltd Invention
US5922546A (en) 1997-08-25 1999-07-13 Smithkline Beecham Corporation Human disintegrin metalloprotease KUZ gene
JP2001521742A (en) * 1997-10-30 2001-11-13 イミュネックス・コーポレーション Svph1-26dna and polypeptides
IL137265D0 (en) * 1998-01-14 2001-07-24 Immunex Corp Testis-specific human svph1-8 proteinase
CA2320422A1 (en) * 1998-02-11 1999-08-19 Immunex Corporation Metalloprotease-disintegrins svph3-13 and svph3-17 dna and polypeptides
US6265199B1 (en) 1998-07-10 2001-07-24 Zymogenetics, Inc. Disintegrin homologs
IL143769D0 (en) 1999-01-21 2002-04-21 Immunex Corp Metalloproteinase-disintegrin family members: svph dnas and polypeptides
WO2000043493A2 (en) * 1999-01-22 2000-07-27 Human Genome Sciences, Inc. Metalloproteinase adam 22
EP1268756A2 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Co. Methods and compositions for modulating integrin-mediated cell-cell interactions

Also Published As

Publication number Publication date
US20060177443A1 (en) 2006-08-10
CA2400040A1 (en) 2001-08-30
WO2001062905A2 (en) 2001-08-30
US20020042368A1 (en) 2002-04-11
EP1259595B1 (en) 2007-04-04
US7074408B2 (en) 2006-07-11
DE60127656D1 (en) 2007-05-16
EP1259595A2 (en) 2002-11-27
NZ521437A (en) 2004-04-30
WO2001062905A3 (en) 2002-03-21
AU4721901A (en) 2001-09-03
DE60127656T2 (en) 2007-12-20
JP2003523768A (en) 2003-08-12
AT358718T (en) 2007-04-15
AU2001247219B2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
DE60136690D1 (en) Axiales wirbelimplantat
DE60119890D1 (en) Handfixierungsvorrichtung
DE60111019D1 (en) Penisprothese
DE60137350D1 (en) Bipolares ablationsgerät
DE60139107D1 (en) Substituierte phenyl-sulfamoyl-carboxamide
DE60105852D1 (en) Fluidmischsystem
DE60111057D1 (en) Intubationsinstrument
DE60111703D1 (en) Modulare hüftprothese
DE60131671D1 (en) Abbaubare amorphe fluoroacrylat-polymere
DE60140693D1 (en) Ankheiten
DE60102572D1 (en) Polyurethanhartschaumstoffe
DE60131262D1 (en) Ubiquitin-ligase-assay
DE60123606D1 (en) Transkutane prothese
DE60116761D1 (en) Adamantanderivate
DE60141333D1 (en) Ioxidlösung
DE60115644D1 (en) Thiazinoxazolidinon
DE60128102D1 (en) Imidazolderivate
DE50110048D1 (en) Härtbare wässrige polyurethandispersionen
DE60121590D1 (en) Pyrazolderivate
DE60144026D1 (en) Off-center-tomosynthese
DE60140430D1 (en) Modulares ofensystem
DE60116104D1 (en) Phasendispersive tomographie
AU6284701A (en) Language-understanding
AU3391801A (en) Pyridinylimidazoles
MXPA02004985A (en) Npyy5 antagonists.